Drug Database · Clinicians

Methylergometrine

Also known as: methylergonovine (US name)

Brands (13) Mergot, Biometrine, Cethergo…Show all

US brand (reference label): Methergine; not a Philippine-registered brand.

Oxytocic (uterine stimulant); Uterotonic (ergot alkaloid); and others PH FDA category

Rx · Prescription drug15 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 3f04ca06-fe52-46d6-96cd-2e77ef6fa36f, version date March 20, 2024 (Methergine · Lupin Pharmaceuticals,Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.

Contraindications

CONTRAINDICATIONS Hypertension; toxemia; pregnancy; and hypersensitivity.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Intramuscularly 1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours. Intravenously 1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds (See WARNINGS.) Orally One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Clinical studies of Methergine did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Dosage forms

Philippines

  • Film-coated tablet: 125 mcg
  • Solution for injection: 200 mcg/mL

Registered products in the Philippines

15 products registered with the Food and Drug Administration (FDA) Philippines list Methylergometrine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products15
Philippine FDA-registered products for Methylergometrine
Package insert
BiometrineMethylergometrine maleate
125 mcg Film-Coated TabletClear PVDC/Alu Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Euro-Health Care Exponents, Inc.
DR-XY39750
Jul 11, 2031
CethergoMethylergometrine Maleate
200 mcg/mL Solution for Injection (IM/ IV)Type I Amber Glass Ampoule x 1 mL (Box of 50’s)
Rx
T.P. Drug Laboratories (1969) Co., Ltd.Thailand
LORDLA PHARMA SALES
DR-XY23015-B
Jul 10, 2028
ErgeMethylergometrine Maleate
125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 50's and 100's)
Rx
JAYSON PHARMACEUTICALS LTD.Bangladesh
BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.
DRP-4222-02
Apr 20, 2027
ErgojenMethylergometrine Maleate
125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Vamsler Phils. Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-3587-03
Nov 12, 2027
ErgometMethylergometrine Maleate
200 mcg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL wrapped in Aluminum Foil Pouch (Box of 5's and 10's)
Rx
Geofman PharmaceuticalsPakistan
Sahar International Trading, Inc.
DRP-8424
Sep 12, 2029
ErgonMethylergometrine Maleate
125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 50’S and 100’s)
Rx
Jayson Pharmaceuticals Ltd.Bangladesh
Aglobal Care, Inc.
DRP-4222
Apr 20, 2027
ErgotecMethylergometrine maleate
125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Aldril Pharmaceuticals, Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-3587-01
Nov 12, 2027
MergoMethylergometrine Maleate
125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
JAYSON PHARMACEUTICALS LTD.Bangladesh
REGIMED PHARMACEUTICAL DISTRIBUTORImporter: AGLOBAL CARE, INC.
DRP-4222-01
Apr 20, 2027
MergotMethylergometrine maleate
125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-3587
Nov 12, 2027
MergotMethylergometrine Maleate
200 mcg/mL Solution for Injection (IM/IV)Amber Glass Ampoule x 1 mL in a Clear Plastic Tray x 10's (Box of 10's and 50's)
Rx
Daewon Pharm. Co., Ltd.Republic of Korea
Solvang Pharmaceuticals, Inc.Importer: D.B. Manix International, Inc.
DRP-2604
May 29, 2031
MergotMethylergometrine Maleate
200 mcg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL Wrapped in Aluminum Foil Pouch Box of 5's and Box of 10's
Rx
Geofman PharmaceuticalsPakistan
Solvang Pharmaceuticals, Inc.Importer: Sahar International Trading, Inc.
DRP-8424-01
Sep 12, 2029
Saph-memMethylergometrine maleate
200 mcg/mL Solution for Injection (I.M./I.V.)USP Type I amber glass ampoule x 1 mL (net content) (Box of 5's, 10's, and 50's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.
DRP-10688
Nov 8, 2031
SaphgometrineMethylergometrine maleate
125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x (Box of 100's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Ollen Pharma Trading, Inc.
DRP-13722
Mar 31, 2028
UterginMethylergometrine (as maleate)
200 mcg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 1 mL in Transparent Plastic Tray (Box of 10's)
Rx
Ciron Drugs & Pharmaceuticals Pvt. Ltd.India
Phil. Pharmawealth, Inc.Trader: Oboi Laboratories
DR-XY38420
Aug 31, 2030
ZemetrinMethylergometrine maleate
125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Janamed CorporationTrader: Solvang Pharmaceuticals, Inc.
DRP-3587-04
Nov 12, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS General This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V administration is considered essential as a lifesaving measure, Methergine (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure.

Intra-arterial or periarterial injection should be strictly avoided. Caution should be exercised in presence of impaired hepatic or renal function. Breast-feeding Mothers should not breast-feed during treatment with Methergine. Milk secreted during this period should be discarded. Methergine may produce adverse effects in the breast-feeding infant.

Methergine may also reduce the yield of breast milk. Mothers should wait at least 12 hours after administration of the last dose of Methergine before initiating or resuming breast feeding. Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm.

Medication errors Inadvertent administration of Methergine to newborn infants has been reported. In these cases of inadvertent neonatal exposure, symptoms such as respiratory depression, convulsions, cyanosis and oliguria have been reported. Usual treatment is symptomatic. However, in severe cases, respiratory and cardiovascular support is required.

Methergine has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. Due to the potential for accidental neonatal exposure, Methergine injection should be stored separately from medications intended for neonatal administration.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine.

Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution.

Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of Methergine.

Beta-blockers Caution should be exercised when Methergine is used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Anesthetics Anesthetics like halothan and methoxyfluran may reduce the oxytocic potency of Methergine. Glyceryl trinitrate and other antianginal drugs Methylergonovine maleate produces vasoconstriction and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs.

No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known. Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.

Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine.

Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).

Less potent CYP 3A4 inhibitors should be administered with caution.

These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.

CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of Methergine.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. Rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. 1 There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product.

Postmarketing Experience The following adverse drug reactions have been derived from post-marketing experience with Methergine via spontaneous case reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.

Nervous system disorders Cerebrovascular accident, paraesthesia Cardiac disorders Ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Category C: Animal reproductive studies have not been conducted with Methergine. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE).

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Mothers should not breast-feed during treatment with Methergine and at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.

The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Methergine (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.

Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%.

Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver. Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.

For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg.

When given intramuscularly, the extent of absorption of Methergine solution was about 25% greater than the tablet. The volume of distribution (Vd ss /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).

A delayed gastrointestinal absorption (T max about 3 hours) of Methergine tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Methylergometrine 200 mcg/mL, 1 mL Ampule₱11.12–₱70.00Reference ₱13.79per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Methergine · Lupin Pharmaceuticals,Inc. [US FDA-approved label, version 3, March 20, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f04ca06-fe52-46d6-96cd-2e77ef6fa36f
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .